tetano
Editor, Senior Moderator
Thyroid
. 2022 Jul 21.
doi: 10.1089/thy.2022.0101. Online ahead of print.
Effect of Inactivated SARS-CoV-2 Vaccine on Thyroid Function and Autoimmunity within 28 days after the Second Dose
Liubing Li[SUP] 1 [/SUP], Xinwen Chen[SUP] 2 [/SUP], Bin Li[SUP] 3 4 [/SUP], Dayue Liu[SUP] 5 [/SUP], Yi-Hao Liu[SUP] 6 7 [/SUP], Ruohui Mo[SUP] 8 [/SUP], Fenghua Lai[SUP] 9 [/SUP], Rengyun Liu[SUP] 10 [/SUP], Sui Peng[SUP] 3 11 [/SUP], Yanbing Li[SUP] 12 [/SUP], Min Liu[SUP] 13 [/SUP], Haipeng Xiao[SUP] 14 [/SUP]
Affiliations
Abstract
Background: The safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is widely appreciated. However, there is limited knowledge regarding the potential impact of SARS-CoV-2 vaccines on the thyroid.
Methods: We performed two prospective clinical trials between April and June, 2021, enrolling recipients of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV and CoronaVac). Thyroid function, antithyroid antibody levels, and SARS-CoV-2 neutralizing antibody (NAb) levels were detected for each participant before receiving the first vaccine dose and 28 days after receiving the second vaccine dose.
Results: A total of 657 recipients participated in the study. The overall median thyroid function and levels of antithyroid antibodies before and after SARS-CoV-2 vaccination were within the normal range. Among the 564 participants with normal thyroid function at baseline, 36 (6.38%; 95% confidence interval (CI): 4.51%-8.73%) developed thyroid dysfunction. Of the 545 recipients with negative antithyroid antibodies at baseline, none developed abnormal antibodies after vaccination. Notably, 75.27% (70/93; 95% CI: 65.24%-83.63%) of the 93 recipients with thyroid dysfunction, returned to normal function after vaccination. The levels of anti-thyroid peroxidase antibody (TPOAb; 96.20%; 95% CI: 89.30%-99.21%) and anti-thyroglobulin antibody (TgAb; 88.31%; 95% CI: 78.97%-94.51%) remained positive after vaccination in most patients with abnormal values at baseline. However, the TgAb levels in more than half of the patients (48/77 ) decreased. All of eleven abnormal thyroid-stimulating hormone (TSH) receptor antibody (TRAb) levels at baseline decreased post-vaccination.
Conclusions: Vaccination with an inactivated SARS-CoV-2 vaccine had no significant adverse impact on thyroid function or antithyroid antibodies within the first 28 days after the second dose.
Clinical trial registration: ChiCTR2100045109 and ChiCTR2100042222.
. 2022 Jul 21.
doi: 10.1089/thy.2022.0101. Online ahead of print.
Effect of Inactivated SARS-CoV-2 Vaccine on Thyroid Function and Autoimmunity within 28 days after the Second Dose
Liubing Li[SUP] 1 [/SUP], Xinwen Chen[SUP] 2 [/SUP], Bin Li[SUP] 3 4 [/SUP], Dayue Liu[SUP] 5 [/SUP], Yi-Hao Liu[SUP] 6 7 [/SUP], Ruohui Mo[SUP] 8 [/SUP], Fenghua Lai[SUP] 9 [/SUP], Rengyun Liu[SUP] 10 [/SUP], Sui Peng[SUP] 3 11 [/SUP], Yanbing Li[SUP] 12 [/SUP], Min Liu[SUP] 13 [/SUP], Haipeng Xiao[SUP] 14 [/SUP]
Affiliations
- PMID: 35864805
- DOI: 10.1089/thy.2022.0101
Abstract
Background: The safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is widely appreciated. However, there is limited knowledge regarding the potential impact of SARS-CoV-2 vaccines on the thyroid.
Methods: We performed two prospective clinical trials between April and June, 2021, enrolling recipients of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV and CoronaVac). Thyroid function, antithyroid antibody levels, and SARS-CoV-2 neutralizing antibody (NAb) levels were detected for each participant before receiving the first vaccine dose and 28 days after receiving the second vaccine dose.
Results: A total of 657 recipients participated in the study. The overall median thyroid function and levels of antithyroid antibodies before and after SARS-CoV-2 vaccination were within the normal range. Among the 564 participants with normal thyroid function at baseline, 36 (6.38%; 95% confidence interval (CI): 4.51%-8.73%) developed thyroid dysfunction. Of the 545 recipients with negative antithyroid antibodies at baseline, none developed abnormal antibodies after vaccination. Notably, 75.27% (70/93; 95% CI: 65.24%-83.63%) of the 93 recipients with thyroid dysfunction, returned to normal function after vaccination. The levels of anti-thyroid peroxidase antibody (TPOAb; 96.20%; 95% CI: 89.30%-99.21%) and anti-thyroglobulin antibody (TgAb; 88.31%; 95% CI: 78.97%-94.51%) remained positive after vaccination in most patients with abnormal values at baseline. However, the TgAb levels in more than half of the patients (48/77 ) decreased. All of eleven abnormal thyroid-stimulating hormone (TSH) receptor antibody (TRAb) levels at baseline decreased post-vaccination.
Conclusions: Vaccination with an inactivated SARS-CoV-2 vaccine had no significant adverse impact on thyroid function or antithyroid antibodies within the first 28 days after the second dose.
Clinical trial registration: ChiCTR2100045109 and ChiCTR2100042222.